Agency Information Collection Activities; Proposed Collection; Comment Request; Tracking Network for PETNet, LivestockNet, and SampleNet, 64533-64535 [2019-25327]
Download as PDF
Federal Register / Vol. 84, No. 226 / Friday, November 22, 2019 / Notices
TABLE 1—NEW DRAFT PRODUCT-SPECIFIC GUIDANCES FOR DRUG PRODUCTS
TABLE 2—REVISED DRAFT PRODUCTSPECIFIC GUIDANCES FOR DRUG
PRODUCTS—Continued
64533
Dated: November 18, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–25326 Filed 11–21–19; 8:45 am]
Active ingredient(s)
Active ingredient(s)
Acetaminophen; Benzhydrocodone hydrochloride.
Betamethasone dipropionate; Calcipotriene.
Cefaclor.
Chlorzoxazone (multiple reference listed
drugs).
Copper.
Dolutegravir sodium; Rilpivirine hydrochloride.
Doxycycline hyclate.
Encorafenib.
Fluorometholone acetate.
Indocyanine green.
Isoniazid; Pyrazinamide; Rifampin.
Isosorbide dinitrate.
Ketoprofen.
Latanoprost; Netarsudil dimesylate.
Lidocaine.
Lorlatinib.
Lovastatin.
Lutetium dotatate Lu-177.
Medroxyprogesterone acetate.
Meloxicam.
Mifepristone.
Migalastat hydrochloride.
Omadacycline tosylate (multiple reference
listed drugs).
Oxymetazoline hydrochloride.
Pimavanserin tartrate.
Sumatriptan succinate.
Tetracaine hydrochloride.
Timolol maleate.
Disopyramide phosphate.
Doxepin hydrochloride.
Estradiol (multiple reference listed drugs).
Estradiol; Levonorgestrel.
Estradiol; Norethindrone acetate.
Ethinyl estradiol; Norelgestromin.
Fentanyl.
Flavoxate hydrochloride.
Granisetron.
Indapamide.
Lidocaine.
Lithium carbonate.
Menthol; Methyl salicylate.
Metformin hydrochloride; Repaglinide.
Methylphenidate.
Mifepristone.
Molindone hydrochloride.
Mycophenolate mofetil.
Nicotine.
Nitrofurantoin, Macrocrystalline.
Nitrofurantoin;
Nitrofurantoin,
Macrocrystalline.
Nitroglycerin (multiple reference listed drugs).
Oxybutynin (multiple reference listed drugs).
Pimecrolimus.
Prednisolone sodium phosphate.
Rivastigmine.
Roflumilast.
Rotigotine.
Scopolamine.
Selegiline.
Sulfacetamide sodium.
Sulfadiazine.
Tazarotene (multiple reference listed drugs).
Terazosin hydrochloride.
Testosterone.
Tinidazole.
Tipiracil hydrochloride; Trifluridine.
Tretinoin (multiple reference listed drugs).
III. Drug Products for Which Revised
Draft Product-Specific Guidances are
Available
FDA is announcing the availability of
revised draft product-specific guidances
for industry for drug products
containing the following active
ingredients:
TABLE 2—REVISED DRAFT PRODUCTSPECIFIC GUIDANCES FOR DRUG
PRODUCTS
khammond on DSKJM1Z7X2PROD with NOTICES
Active ingredient(s)
Adapalene (multiple reference listed drugs).
Adapalene; Benzoyl peroxide (multiple reference listed drugs).
Azacitidine.
Baclofen.
Benzoyl peroxide; Clindamycin phosphate
(multiple reference listed drugs).
Benzoyl peroxide; Erythromycin (multiple reference listed drugs).
Capsaicin.
Cariprazine hydrochloride.
Clindamycin phosphate (multiple reference
listed drugs).
Clindamycin phosphate; Tretinoin.
Clonidine.
Clonidine hydrochloride.
Dapsone (multiple reference listed drugs).
Diclofenac epolamine.
Didanosine.
VerDate Sep<11>2014
16:57 Nov 21, 2019
Jkt 250001
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–0736]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Tracking Network
for PETNet, LivestockNet, and
SampleNet
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, the Agency, or
we) is announcing an opportunity for
public comment on the proposed
collection of certain information by the
Agency. Under the Paperwork
Reduction Act of 1995 (PRA), Federal
Agencies are required to publish notice
in the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on our use of a
tracking network to collect and share
safety information about animal food
from Federal, State, and Territorial
Agencies.
SUMMARY:
Submit either electronic or
written comments on the collection of
information by January 21, 2020.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before January 21,
2020. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of January 21, 2020.
Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
For a complete history of previously
published Federal Register notices
related to product-specific guidances, go
to https://www.regulations.gov and
enter Docket No. FDA–2007–D–0369.
These draft guidances are being
issued consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). These draft guidances, when
finalized, will represent the current
thinking of FDA on, among other things,
the product-specific design of BE
studies to support ANDAs. They do not
establish any rights for any person and
are not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
DATES:
IV. Electronic Access
Electronic Submissions
Persons with access to the internet
may obtain the draft guidances at either
https://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/
Guidances/default.htm or https://
www.regulations.gov.
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
E:\FR\FM\22NON1.SGM
22NON1
64534
Federal Register / Vol. 84, No. 226 / Friday, November 22, 2019 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–0736 for ‘‘Agency Information
Collection Activities; Proposed
Collection; Comment Request; Tracking
Network for PETNet, LivestockNet, and
SampleNet.’’ Received comments, those
filed in a timely manner (see
ADDRESSES), will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
VerDate Sep<11>2014
16:57 Nov 21, 2019
Jkt 250001
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Jonnalynn Capezzuto, Office of
Operations, Food and Drug
Administration, Three White Flint
North, 10A–12M, 11601 Landsdown St.,
North Bethesda, MD 20852, 301–796–
3794, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3521), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Tracking Network for PETNet,
LivestockNet, and SampleNet
OMB Control Number 0910–0680—
Extension
The Center for Veterinary Medicine
and the Partnership for Food Protection
developed a web-based tracking
network (the tracking network) to allow
Federal, State, and Territorial regulatory
and public health Agencies to share
safety information about animal food.
Information is submitted to the tracking
network by regulatory and public health
Agency employees with membership
rights. The efficient exchange of safety
information is necessary because it
improves early identification and
evaluation of a risk associated with an
animal food product. We use the
information to assist regulatory
Agencies to quickly identify and
evaluate a risk and take whatever action
is necessary to mitigate or eliminate
exposure to the risk. Earlier
identification and communication with
respect to emerging safety information
may also mitigate the potential adverse
economic impact for the impacted
parties associated with such safety
issues. The tracking network was
developed under the requirements set
forth under section 1002(b) of the Food
and Drug Administration Amendments
Act of 2007 (FDAAA) (Pub. L. 110–085).
Section 1002(b) of the FDAAA required
FDA, in relevant part, to establish a pet
food early warning alert system.
The tracking network collects: (1)
Reports of pet food-related illness and
product defects associated with dog
food, cat food, and food for other pets,
which are submitted via the Pet Event
Tracking Network (PETNet); (2) reports
of animal food-related illness and
product defects associated with animal
food for livestock animals, aquaculture
species, and horses (LivestockNet); and
(3) reports about animal food laboratory
samples considered adulterated by State
or FDA regulators (SampleNet).
E:\FR\FM\22NON1.SGM
22NON1
Federal Register / Vol. 84, No. 226 / Friday, November 22, 2019 / Notices
PETNet and LivestockNet reports
share the following common data
elements, the majority of which are drop
down menu choices: product details
(product name, lot code, product form,
and the manufacturer or distributor/
packer (if known)), the species affected,
number of animals exposed to the
product, number of animals affected,
body systems affected, product
problem/defect, date of onset or the date
product problem was detected, the State
where the incident occurred, the origin
of the information, whether there are
supporting laboratory results, and
contact information for the reporting
member (i.e., name, telephone number
will be captured automatically when
member logs in to the system). For the
LivestockNet report, additional data
elements specific to livestock animals
are captured: Product details (indication
of whether the product is a medicated
product, product packaging, and
intended purpose of the product), class
of the animal species affected, and
production loss. For PETNet reports, the
only additional data field is the animal
life stage. The SampleNet reports have
the following data elements, many of
which are drop down menu choices:
Product information (product name, lot
code, guarantor information, date and
location of sample collection, and
product description); laboratory
information (sample identification
64535
number, the reason for testing, whether
the food was reported to the Reportable
Food Registry, who performed the
analysis); and results information
(analyte, test method, analytical results,
whether the results contradict a label
claim or guarantee, and whether action
was taken as a result of the sample
analysis).
Description of Respondents:
Voluntary respondents to this collection
of information are Federal, State, and
Territorial regulatory and public health
Agency employees with membership
access to the Animal Feed Network.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Total annual
responses
Average burden
per response
Total hours
PETNet ................................................................
LivestockNET ......................................................
SampleNet ...........................................................
20
20
20
5
5
5
100
100
100
0.25 (15 minutes) ...........
0.25 (15 minutes) ...........
0.25 (15 minutes) ...........
25
25
25
Total .............................................................
........................
........................
........................
........................................
75
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Based on a review of the information
collection since our last request for
OMB approval, we have made no
adjustments to our burden estimate.
Dated: November 14, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–25327 Filed 11–21–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Medical Devices;
Shortages Data Collection System
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
SUMMARY:
VerDate Sep<11>2014
16:57 Nov 21, 2019
Jkt 250001
Fax written comments on the
collection of information by December
23, 2019.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0491. Also
include the FDA docket number found
in brackets in the heading of this
document.
DATES:
FOR FURTHER INFORMATION CONTACT:
[Docket No. FDA–2012–N–0197]
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
responses per
respondent
Number of
respondents
Activity
JonnaLynn Capezzuto, Office of
Operations, Food and Drug
Administration, Three White Flint
North, 10A–12M, 11601 Landsdown St.,
North Bethesda, MD 20852, 301–796–
3794, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Medical Devices; Shortages Data
Collection System
OMB Control Number 0910–0491—
Reinstatement
Under section 1003(d)(2) of the
Federal Food, Drug, and Cosmetic Act
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
(FD&C Act) (21 U.S.C. 393(d)(2)), the
Commissioner of Food and Drugs is
authorized to implement general powers
(including conducting research) to carry
out effectively the mission of FDA.
After the events of September 11,
2001, and as part of broader
counterterrorism and emergency
preparedness activities, FDA’s Center
for Devices and Radiological Health
(CDRH) began developing operational
plans and interventions that would
enable CDRH to anticipate and respond
to medical device shortages that might
arise in the context of federally declared
disasters/emergencies or regulatory
actions. In particular, CDRH identified
the need to acquire and maintain
detailed data on domestic inventory,
manufacturing capabilities, distribution
plans, and raw material constraints for
medical devices that would be in high
demand and/or would be vulnerable to
shortages in specific disaster/emergency
situations or following specific
regulatory actions. Such data could
support prospective risk assessment,
help inform risk mitigation strategies,
support real-time decision making by
the Department of Health and Human
Services during actual emergencies or
emergency preparedness exercises, and
mitigate or prevent harm to the public
health.
The data collection process will
consist of an initial telephone call to
firms who have been identified as
E:\FR\FM\22NON1.SGM
22NON1
Agencies
[Federal Register Volume 84, Number 226 (Friday, November 22, 2019)]
[Notices]
[Pages 64533-64535]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-25327]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-0736]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Tracking Network for PETNet, LivestockNet, and
SampleNet
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is
announcing an opportunity for public comment on the proposed collection
of certain information by the Agency. Under the Paperwork Reduction Act
of 1995 (PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on our use of a tracking network
to collect and share safety information about animal food from Federal,
State, and Territorial Agencies.
DATES: Submit either electronic or written comments on the collection
of information by January 21, 2020.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before January 21, 2020. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of January 21, 2020. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are postmarked or the delivery
service acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically,
[[Page 64534]]
including attachments, to https://www.regulations.gov will be posted to
the docket unchanged. Because your comment will be made public, you are
solely responsible for ensuring that your comment does not include any
confidential information that you or a third party may not wish to be
posted, such as medical information, your or anyone else's Social
Security number, or confidential business information, such as a
manufacturing process. Please note that if you include your name,
contact information, or other information that identifies you in the
body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2016-N-0736 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; Tracking Network for PETNet,
LivestockNet, and SampleNet.'' Received comments, those filed in a
timely manner (see ADDRESSES), will be placed in the docket and, except
for those submitted as ``Confidential Submissions,'' publicly viewable
at https://www.regulations.gov or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Jonnalynn Capezzuto, Office of
Operations, Food and Drug Administration, Three White Flint North, 10A-
12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794,
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3521), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Tracking Network for PETNet, LivestockNet, and SampleNet
OMB Control Number 0910-0680--Extension
The Center for Veterinary Medicine and the Partnership for Food
Protection developed a web-based tracking network (the tracking
network) to allow Federal, State, and Territorial regulatory and public
health Agencies to share safety information about animal food.
Information is submitted to the tracking network by regulatory and
public health Agency employees with membership rights. The efficient
exchange of safety information is necessary because it improves early
identification and evaluation of a risk associated with an animal food
product. We use the information to assist regulatory Agencies to
quickly identify and evaluate a risk and take whatever action is
necessary to mitigate or eliminate exposure to the risk. Earlier
identification and communication with respect to emerging safety
information may also mitigate the potential adverse economic impact for
the impacted parties associated with such safety issues. The tracking
network was developed under the requirements set forth under section
1002(b) of the Food and Drug Administration Amendments Act of 2007
(FDAAA) (Pub. L. 110-085). Section 1002(b) of the FDAAA required FDA,
in relevant part, to establish a pet food early warning alert system.
The tracking network collects: (1) Reports of pet food-related
illness and product defects associated with dog food, cat food, and
food for other pets, which are submitted via the Pet Event Tracking
Network (PETNet); (2) reports of animal food-related illness and
product defects associated with animal food for livestock animals,
aquaculture species, and horses (LivestockNet); and (3) reports about
animal food laboratory samples considered adulterated by State or FDA
regulators (SampleNet).
[[Page 64535]]
PETNet and LivestockNet reports share the following common data
elements, the majority of which are drop down menu choices: product
details (product name, lot code, product form, and the manufacturer or
distributor/packer (if known)), the species affected, number of animals
exposed to the product, number of animals affected, body systems
affected, product problem/defect, date of onset or the date product
problem was detected, the State where the incident occurred, the origin
of the information, whether there are supporting laboratory results,
and contact information for the reporting member (i.e., name, telephone
number will be captured automatically when member logs in to the
system). For the LivestockNet report, additional data elements specific
to livestock animals are captured: Product details (indication of
whether the product is a medicated product, product packaging, and
intended purpose of the product), class of the animal species affected,
and production loss. For PETNet reports, the only additional data field
is the animal life stage. The SampleNet reports have the following data
elements, many of which are drop down menu choices: Product information
(product name, lot code, guarantor information, date and location of
sample collection, and product description); laboratory information
(sample identification number, the reason for testing, whether the food
was reported to the Reportable Food Registry, who performed the
analysis); and results information (analyte, test method, analytical
results, whether the results contradict a label claim or guarantee, and
whether action was taken as a result of the sample analysis).
Description of Respondents: Voluntary respondents to this
collection of information are Federal, State, and Territorial
regulatory and public health Agency employees with membership access to
the Animal Feed Network.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
Activity Number of responses per Total annual Average burden per response Total hours
respondents respondent responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
PETNet.................................... 20 5 100 0.25 (15 minutes)........................... 25
LivestockNET.............................. 20 5 100 0.25 (15 minutes)........................... 25
SampleNet................................. 20 5 100 0.25 (15 minutes)........................... 25
-------------------------------------------------------------------------------------------------------------
Total................................. .............. .............. .............. ............................................ 75
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Based on a review of the information collection since our last
request for OMB approval, we have made no adjustments to our burden
estimate.
Dated: November 14, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-25327 Filed 11-21-19; 8:45 am]
BILLING CODE 4164-01-P